Lexaria Bioscience (LEXX) Total Debt Growth (1y) (2012 - 2022)
Lexaria Bioscience (LEXX) Total Debt Growth (1y) (2012 - 2022) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.10% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 12.42% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -57.72% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 3.78% |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2022 | 5.32% |
| Aug 31, 2021 | -91.13% |
| May 31, 2021 | -87.13% |
| Feb 28, 2021 | 369.19% |
| Nov 30, 2020 | 217.30% |
| Aug 31, 2020 | 85.82% |
| May 31, 2020 | 177.93% |
| Feb 29, 2020 | -71.54% |
| Nov 30, 2019 | 71.79% |
| Aug 31, 2019 | 512.30% |
| May 31, 2019 | 130.46% |
| Feb 28, 2019 | 0.48% |
| Nov 30, 2018 | -13.45% |
| Aug 31, 2018 | -81.60% |
| May 31, 2018 | 22.35% |
| Feb 28, 2018 | -98.02% |
| Nov 30, 2017 | -93.30% |
| Aug 31, 2017 | -87.12% |
| May 31, 2017 | -97.10% |
| Feb 28, 2017 | 18.64% |